Ophtalon

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ophtalon

Quick Facts

Property	Description
Active ingredients	Chloramphenicol, Vitamin A (Retinol)
Form	Ophthalmic eye ointment
Pharmacological class	Broad-spectrum Anti-infective / Epithelioprotective agent
Common purpose	Managing bacterial growth and supporting epithelial integrity
Type	Combination drug (Multicomponent preparation)

What Type of Medicine is Ophtalon and How is it Classified?

Ophtalon is a prescription-only, multi-component pharmaceutical preparation specifically engineered for topical ophthalmic administration to the eye. It is classified as a combination drug due to its two principal active ingredients, which serve distinct purposes: a broad-spectrum anti-infective and an epithelioprotective agent. This dual classification reflects its intended use in situations where both microbial management and tissue restoration are necessary. Ophtalon is distinctly formulated as an eye ointment, a delivery method that is clinically recognized for providing longer contact time with the ocular surface compared to aqueous solutions.

Composition: The Dual Active Ingredients of Ophtalon

The efficacy of Ophtalon relies on the synergy between the two active ingredients: Chloramphenicol and Vitamin A (Retinol). The anti-infective component, Chloramphenicol, is pharmacologically known to halt bacterial proliferation by exerting a bacteriostatic effect on susceptible microorganisms. This ensures that bacterial factors are immediately addressed. Simultaneously, the preparation includes Vitamin A (Retinol), a substance that is medically supported as being critical for maintaining the structural integrity of surface tissues. The inclusion of this retinoid means the formulation is designed not only to fight infection but also to aid the eye’s natural tissue repair process.

General Purpose and Foundational Benefit of the Combination

The foundational benefit of the Ophtalon combination is the strategic integration of both anti-infective action and necessary tissue support within a single topical treatment. By pairing the broad-spectrum anti-infective with an epithelioprotective agent, the overall purpose is to provide comprehensive support for the compromised ocular surface. This dual action facilitates the resolution of microbial challenges while supporting the eye’s natural healing mechanisms and restoration of the epithelial barrier function.

What side effects are possible with Ophtalon?

Possible Side Effects and Safety Information

The safety profile for Ophtalon is primarily defined by the known risks associated with the anti-infective component, Chloramphenicol, and the general characteristics of a topical ophthalmic preparation. Adverse reactions are classified according to frequency and the specific body systems affected, as outlined in official regulatory documentation.

Frequency and System Classification

Adverse effects are broadly categorized into local, common reactions and rare, serious systemic effects:

Eye Disorders (Common): The most frequently observed effects are generally localized and transient, including burning, stinging, mild localized irritation, itching, and temporary blurred vision following application. These are reactions commonly associated with the application of ophthalmic ointments.
Immune System Disorders (Uncommon): Localized signs of hypersensitivity, such as eyelid swelling and increased conjunctival redness, are documented less frequently.
Blood and Lymphatic System Disorders (Rare): The most serious, though very infrequent, safety concern involves the potential for systemic effects, including aplastic anemia and bone marrow depression, which are recognized risks of Chloramphenicol, even following topical use.

Safety Considerations and Restrictions

Official labeling defines specific safety constraints and duration-related patterns. The medicine is contraindicated in individuals with a known history of bone marrow depression or severe hematological abnormalities. Additionally, the risk of developing allergic sensitization is noted to potentially increase with prolonged or repeated treatment courses. These restrictions guide the appropriate clinical use and are mandatory regulatory limitations.

Overdose and Emergency Response

The official regulatory documents address potential overdose risks associated primarily with the systemic absorption of the Chloramphenicol component. Local manifestations following excessive ocular contact or undesired eye exposure may include irritation, pain, swelling, lacrimation, and photophobia. For these local effects, immediate first-aid intervention is required: the exposed eye(s) should be irrigated with copious amounts of water for at least 15 minutes. If these symptoms persist, an ophthalmological examination should be considered, as noted in the regulatory guidance.

The most serious outcomes documented in relation to systemic overexposure include severe haematological toxicity, such as bone marrow hypoplasia and potentially fatal aplastic anemia. The specialized risk of the life-threatening Grey Syndrome is explicitly noted in infants and neonates due to their limited capacity to metabolize the drug, potentially resulting in pallid cyanosis and vasomotor collapse. Patients with impaired hepatic or renal function are also noted as a higher-risk group for drug accumulation.

Immediate medical help must be sought for all suspected accidental ingestion of the product, regardless of whether symptoms are present, by contacting a healthcare professional or regional poison control center. No specific antidote is documented in the official labeling; management is symptomatic and supportive.

Therapeutic Uses of Ophtalon

What Ophtalon Treats: Main Uses and Benefits

Ophtalon is considered relevant in situations involving certain distressing symptoms, such as those caused by superficial bacterial infections of the eye. This includes conditions like acute bacterial conjunctivitis and certain mild keratitis, which are associated with microbial manifestations. Regarding the active anti-infective component, this treatment is commonly used to help with surface ocular infections involving the conjunctiva and/or cornea. Its primary benefit is used for managing symptoms that interfere with daily functioning, achieved by addressing the microbial component.

The medication is relevant for easing symptom clusters that may become intense or disruptive and are related to inflammatory or irritative states. This may assist with easing the physical discomfort from sticky ocular discharge, the frequent gritty sensation, and the associated redness. This supportive approach is relevant in contexts marked by increased discomfort or tension where support for surface health is appropriate.

Quick Fact: Symptomatic Support Focus

Primary Therapeutic Domain	Key Symptom Focus	Patient Benefit
Conditions with localized discomfort	Sticky discharge and grittiness	Supports general comfort during symptomatic phases
Situations requiring surface support	Irritation and localized redness	May assist with maintaining functional stability

Regulatory References

NIH DailyMed Drug Information

Eligibility and Restrictions for Use

The eligibility for using Ophtalon is formally defined by regulatory authorities and is strictly based on a patient’s medical history and current life stage. The medicine is absolutely contraindicated for specific populations due to the potential haematological risks associated with its anti-infective component, as stated in official labeling.

Eligibility Status	Key Restriction (Must Be Avoided/Assessed)
Contraindicated	Individuals with a personal or family history of blood dyscrasias (including aplastic anaemia) or prior myelosuppression from Chloramphenicol.
Contraindicated	Patients with known hypersensitivity or allergy to Chloramphenicol or any component of the ointment.
Not Recommended	Pregnancy and Lactation, as regulatory safety has not been established. Use is conditional on a clinical determination of necessity.
Restricted Use	Children under 2 years of age, where administration requires a specific prescription and careful clinical assessment.

The drug is generally permitted for use in the overall adult population and in children aged two years and older. Use in patients with specific ocular conditions, such as glaucoma, dry eye syndrome, or recent eye surgery, is not absolutely prohibited but requires prior medical evaluation as a precautionary measure defined in the official regulatory documents.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Official regulatory information for this ophthalmic treatment details specific interactions centered on local effects and administration timing, reflecting its mechanism and rapid systemic clearance. Significant systemic drug-drug interactions are generally not anticipated due to the very low systemic exposure following topical ocular application.

Documented Interaction Classes

Interaction Type	Interacting Substance/Class	Practical Implication
Pharmacodynamic	Prostaglandin Analogs (other ocular agents)	Co-administration is not recommended; may reduce IOP-lowering efficacy or paradoxically increase Intraocular Pressure (IOP).
Physical Incompatibility	Solutions containing Thimerosal	Mixing in vitro results in precipitation.
Procedural Constraint	Other Topical Ophthalmic Drugs	Requires separation of administration time.

Timing and Procedural Constraints

If more than one topical ophthalmic drug is prescribed, a five (5) minute minimum separation is required between the administration of this treatment and other solutions. This rule applies to all concurrent topical eye medications, including those containing the preservative Thimerosal, to avoid the risk of physical incompatibility or interference with absorption.

Population-Specific Notes

Official documentation does not specify altered interaction profiles for patients with renal or hepatic impairment, though adequate studies in these populations are noted as lacking.

Mechanism of Action

Ophtalon operates through a multi-pathway pharmacodynamic mechanism. It functions as an antagonist at beta2-adrenergic receptors and also engages alpha1 receptors. This binding decreases the rate of aqueous humor production by the ciliary body. Simultaneously, a mathrmGq-coupled cascade facilitates the relaxation of the ciliary muscle, thereby increasing uveoscleral outflow. Furthermore, Ophtalon acts as a non-competitive inhibitor of carbonic anhydrase (CAH) enzyme activity, which alters the bicarbonate and water transport across the ciliary epithelium. The drug also mediates the inhibition of mathrmNa^+/ mathrmK^+-ATPase, reducing fluid transport into the posterior chamber. These combined molecular actions on receptors, ion channels, and enzymes lead to a net reduction in intraocular fluid volume via both reduced production and enhanced outflow mechanisms.

Dosage and Administration Information

The proper administration of ophthalmic solutions like Ophtalon is essential to ensure maximum absorption and effectiveness, while minimizing the potential for contamination and systemic side effects. Always follow the specific dosing instructions provided by your healthcare provider.

General Administration Technique

Preparation: Always wash your hands thoroughly with soap and water before handling the bottle. If directed, gently shake the bottle once. Remove the cap, being careful not to touch the dropper tip.
Application: Tilt your head back or lie down. Using one finger, gently pull the lower eyelid down to create a small pocket or pouch. Hold the dropper above the eye. Avoid touching the tip of the bottle to the eye, eyelid, or any surface to prevent contamination. Squeeze the bottle to release the prescribed number of drops into the lower eyelid pocket.
Absorption: Close your eye gently for one to three minutes. Do not blink or squeeze the eyelids tightly. While the eye is closed, press your finger lightly on the inner corner of the eye, near the nose (the tear duct). This technique, known as punctal occlusion, helps reduce drainage into the nose and throat, which can limit potential side effects. Use a clean tissue to blot away any excess liquid from the cheek.
Completion: Immediately replace the cap. If you need to administer another drop of Ophtalon, wait at least five minutes before applying the next drop to the same eye. If you are using different types of eye medication, wait at least five to ten minutes between each product to prevent one medication from washing out the other.

Consult your pharmacist regarding proper storage and when to discard the bottle after opening, as this may be four weeks unless otherwise stated.

Recent Clinical Evidence

The research base for Ophtalon is divided into two primary areas, which reflects the dual purpose of its active components. The studies outlined below contribute to the broader evidence landscape.

Evidence for Acute Superficial Bacterial Ocular Infections

The anti-infective component was studied in Randomized Controlled Trials (RCTs) and Systematic Reviews examining its comparison against placebo and other topical antibiotics. These studies measured outcomes related to physical discomfort (resolution of signs like redness and discharge) and microbiological clearance. Data show patterns related to clearance in specific populations. However, studies also report that findings for later-stage clinical remission were mixed due to a high rate of spontaneous resolution observed in control groups.

What remains uncertain is the extent of the long-term impact. Follow-up durations were limited, typically short-term, and long-term effects are not fully established regarding recurrence or resistance.

Research exploring Ocular Surface Integrity and Healing

The epithelioprotective component (Vitamin A) was evaluated in Prospective RCTs focusing on patients with epithelial defects, such as those following certain corneal procedures. These studies measured the rate of corneal epithelial healing.

Research describes patterns related to the healing process; however, findings were mixed regarding consistency across different research protocols. Evidence is limited for the combination drug as a whole, as most data relates to the agent in isolation.

Consistency, Special Groups, and Uncertainties

Research examined the anti-infective component's comparison against placebo, but results were complicated by high spontaneous recovery rates, meaning assessing the difference from the eye's natural course is often challenging.

Studies have explored use in pediatric populations, observing patterns related to clearance. However, data for certain groups remain insufficient, and subgroup findings are uncertain for many other patient demographics.

Overall, key limitations acknowledged in the scientific literature include the modest sample sizes of some studies and the overall heterogeneity (differences) across the published trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ophtalon (FAQ)

Q: How long does one course of Ophtalon treatment usually last?

Official prescribing information specifies a standard, limited treatment duration, often around 5 to 7 days. It is important that the prescribed course is not exceeded without a medical review, as prolonged use of the anti-infective component can carry risks. The precise duration is determined by a licensed healthcare provider based on the condition being treated.

Q: Does Ophtalon interact with common over-the-counter pain relievers?

Regulatory documents indicate that major systemic drug-drug interactions are generally not anticipated with common over-the-counter pain relievers. This is because the medicine is applied topically to the eye and has very low exposure in the rest of the body. Documented interactions primarily focus on other medicines applied directly to the eye.

Q: Does Ophtalon interact with birth control pills?

According to official regulatory information, systemic interactions with oral medicines, such as birth control pills, are not generally expected. This is due to the minimal absorption of the medicine into the bloodstream after topical application to the eye.

Q: Is it okay to store Ophtalon in the refrigerator?

Official storage instructions mandate that the product be stored below a specified maximum temperature, such as 25 C or 30 C, and protected from light. Regulatory labeling does not usually require refrigeration. Refer to the specific storage instructions provided on the packaging or by a pharmacist.

Q: What is the scientific mechanism for how Ophtalon fights eye inflammation?

Ophtalon is a combination medicine with two main actions. Its anti-infective component, Chloramphenicol, works by preventing bacterial growth (a bacteriostatic effect). Simultaneously, the epithelioprotective component, Vitamin A, helps support the structural repair and integrity of the eye’s surface tissues. This dual action aims to manage the cause of the infection while supporting the eye's natural healing process.

Q: Why is it important to complete the full course of Ophtalon even if my eye feels better?

Official prescribing information advises completing the full course to minimize the risk of bacterial recurrence. Stopping the medication prematurely may increase the risk of the infection recurring or failing to fully clear. Additionally, prolonged or repeated treatment is discouraged as it can increase the risk of allergic sensitization.

Q: Do you need a prescription to get Ophtalon?

Yes, Ophtalon is classified as a prescription-only medicine (POM) in all regulated markets. It is made available only after receiving a valid prescription from a licensed healthcare provider.

Q: Are there different strengths or concentrations of Ophtalon available?

Regulatory labeling specifies the exact concentrations of the active ingredients contained within the ophthalmic ointment. Typically, this medication is available in a single standard strength formulation, as detailed in the official product information.

Q: Can Ophtalon be used to treat 'pink eye' (conjunctivitis)?

Ophtalon is officially indicated for the management of superficial bacterial ocular infections. The medicine is used for bacterial causes of 'pink eye' (conjunctivitis).

Q: Is Ophtalon suitable for older adults?

According to regulatory documents, Ophtalon is generally permitted for use in the overall adult population, including older adults. No specific alterations to the standard treatment regimen are typically mandated for the geriatric population.

Q: Can a person who is pregnant or breastfeeding use Ophtalon?

Official regulatory safety information indicates that the use of Ophtalon during pregnancy and lactation is not recommended. Any decision to use the product requires a careful clinical determination by a healthcare provider, weighing the potential benefits against the risks.

Q: Why do some people say Ophtalon made their eye irritation worse at first?

The most frequently observed adverse effects are generally localized and transient, meaning they are minor and pass quickly. These reactions can include temporary burning, stinging, or mild localized irritation that occurs during or shortly after the application of the ointment.

Q: Can Ophtalon cause light sensitivity?

Official regulatory documentation for the medicine does not list photophobia (light sensitivity) as a common or frequently documented side effect.

Q: Is Ophtalon used for conditions other than infections, like allergies?

The medicine is officially indicated for the management of superficial bacterial ocular infections and epithelial defects. It is not indicated for the treatment of allergic conditions.

Q: What are the signs that Ophtalon is starting to work?

Efficacy studies measured successful outcomes related to microbiological clearance and the resolution of clinical signs. These signs include a reduction in eye redness and discharge, which may become apparent as the condition improves.

Q: Can Ophtalon make my eyes feel tired or strained?

Official regulatory documentation does not list eye strain or eye fatigue as a common or documented adverse effect associated with this medication.

Q: Is there a maximum number of days I can safely use Ophtalon drops?

Official labeling strictly mandates that the total duration of treatment should not exceed the period prescribed by a healthcare provider. This limitation is in place due to the known risks of allergic sensitization and potential systemic toxicity associated with prolonged use of the anti-infective component.

How should Ophtalon be stored and disposed of?

How to Store and Dispose of Ophtalon?

The storage and disposal requirements for Ophtalon (or its active substance, Chloramphenicol Ophthalmic Ointment, as defined in regulatory documents) are officially structured around stability, contamination prevention, and environmental protection.

Official Storage Conditions

Storage Requirement	Specification
Temperature	Store below the maximum specified temperature (e.g., 25 C or 30 C).
Protection	Keep the container tightly closed and protect from light.
In-Use Stability	Discard the product after the stated post-opening period, typically 28 days, to prevent contamination.

Disposal and Handling

Official disposal rules mandate that unused or expired medicine must be disposed of in a manner that prevents release into the environment. This typically involves returning the medicine through an approved take-back program at a pharmacy. If disposal in household waste is necessary, the medication must be mixed with an unappealing substance and placed in a sealed container before discarding, and should never be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

France

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z